http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MY-132062-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
filingDate 1995-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_042634da70718de2db904bc21285ae36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_473dcf1dc9c8134584d0fba65fcb0036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_622e2b26049c4235b63c4a1dfdee08b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f0794995559a2efe556150433665b1f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd353bc9b009350567061c9d0ce4b4a2
publicationDate 2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MY-132062-A
titleOfInvention Apolipoprotein-b synthesis inhibitors
abstract THE PRESENT INVENTION PROVIDES NOVEL COMPOUNDS OF FORMULA( FORMULA 1 )THE N-OXIDES, THE STEREOCHEMICALLY ISOMERIC FORMS THEREOF, AND THE PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, WHEREIN A AND B TAKEN TOGETHER FORM A BIVALENT RADICAL OF FORMULA :-N=CH- (A), -CH=N- (B), -CH2-CH2- (C), -CH=CH- (D), -C(=O)-CH2- (E), -CH2-C(=O)- (F); R1 IS HYDROGEN, C1-6ALKYL, OR HALO; R2 IS HYDROGEN OR HALO; R3 IS HYDROGEN; C1-8ALKYL; C3-6CYCLOALKYL OR C1-8ALKYL SUBSTITUTED WITH HYDROXY, OXO, C3-6CYCLOALKYL OR ARYL. HET IS FIVE- OR SIX-MEMBERED OPTIONALLY SUBSTITUTED HETEROCYCLIC RING. THE USE AS A MEDICINE, ESPECIALLY AS A LIPID LOWERING AGENT IS DISCLOSED AS WELL AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR PREPARING COMPOUNDS AND COMPOSITIONS.
priorityDate 1994-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID54225
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425193155
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID238055
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID494004
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID338
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID783
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457655803

Total number of triples: 34.